Cancer epidemiology · 2026
Temporal evolution of gastric adenocarcinoma in the United States, 2000-2023: Incidence, presentation, registry-recorded treatment, and survival.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lai Hongkun, Zou Liaonan, Li Hongming
Аннотация
BACKGROUND: We assessed contemporaneous changes in gastric adenocarcinoma incidence, presentation, registry-recorded treatment, and survival.
METHODS: Two complementary analyses used Surveillance, Epidemiology, and End Results (SEER) 17 data. Incidence during 2000-2023 was analyzed using Joinpoint regression. A clinical cohort diagnosed during 2004-2023 at prespecified stomach subsites (C16.1-C16.6, C16.8, and C16.9) was compared across four periods. Surgery trends were decomposed into stage-composition and within-stage components. Outcomes included overall survival (OS), cause-specific survival (CSS), and 36-month restricted mean survival time (RMST); adjusted Cox models separately summarized associations over 0-60 months.
RESULTS: The clinical cohort comprised 66,391 tumor records from 66,025 patients. Incidence declined during 2000-2019 (annual percent change, -1.32%; 95% CI, -1.61% to -1.08%) and increased during 2019-2023 (4.96%; 95% CI, 2.51-9.91%). Comparing 2004-2008 with 2019-2023, distant-stage disease increased from 36.1% to 43.0%, whereas surgery among records with known surgery status decreased from 51.9% to 36.3%. Stage-composition change represented 25.7% of the surgery decline. Recorded chemotherapy increased from 35.7% to 54.4%. Median potential follow-up was 206.0 versus 27.4 months; latest-period fixed-time estimates were reported at 12 and 36 months. Three-year OS increased from 25.2% to 29.1% and CSS from 31.4% to 35.6%. Unadjusted 36-month RMST differences were 1.80 months (95% CI, 1.47-2.15) for OS and 1.86 months (95% CI, 1.53-2.22) for CSS.
CONCLUSIONS: Distant-stage presentation became more frequent while recorded surgery declined and short-term survival improved modestly. Within-stage changes represented most of the surgery decline. Additional registry years are needed to assess persistence of the post-2019 incidence increase.
METHODS: Two complementary analyses used Surveillance, Epidemiology, and End Results (SEER) 17 data. Incidence during 2000-2023 was analyzed using Joinpoint regression. A clinical cohort diagnosed during 2004-2023 at prespecified stomach subsites (C16.1-C16.6, C16.8, and C16.9) was compared across four periods. Surgery trends were decomposed into stage-composition and within-stage components. Outcomes included overall survival (OS), cause-specific survival (CSS), and 36-month restricted mean survival time (RMST); adjusted Cox models separately summarized associations over 0-60 months.
RESULTS: The clinical cohort comprised 66,391 tumor records from 66,025 patients. Incidence declined during 2000-2019 (annual percent change, -1.32%; 95% CI, -1.61% to -1.08%) and increased during 2019-2023 (4.96%; 95% CI, 2.51-9.91%). Comparing 2004-2008 with 2019-2023, distant-stage disease increased from 36.1% to 43.0%, whereas surgery among records with known surgery status decreased from 51.9% to 36.3%. Stage-composition change represented 25.7% of the surgery decline. Recorded chemotherapy increased from 35.7% to 54.4%. Median potential follow-up was 206.0 versus 27.4 months; latest-period fixed-time estimates were reported at 12 and 36 months. Three-year OS increased from 25.2% to 29.1% and CSS from 31.4% to 35.6%. Unadjusted 36-month RMST differences were 1.80 months (95% CI, 1.47-2.15) for OS and 1.86 months (95% CI, 1.53-2.22) for CSS.
CONCLUSIONS: Distant-stage presentation became more frequent while recorded surgery declined and short-term survival improved modestly. Within-stage changes represented most of the surgery decline. Additional registry years are needed to assess persistence of the post-2019 incidence increase.